Haemonetics Corporation (HAE) debt

What Haemonetics owes, when it comes due, and what it costs to carry, from the balances and cash flows the company reports to the U.S. Securities and Exchange Commission.

At a glance

MetricJun 2026Jun 2025Change
Total debt$1.17B$1.22B−$51M
Due within a year$5M$304M−$299M
Long-term debt$1.17B$921M+$248M
Cash and equivalents$223M$293M−$70M
Net debt$951M$932M+$19M

Debt over time

Total debt by quarter
$762MSep 2023$871MDec 2023$808MMar 2024$1.2BJun 2024$1.2BSep 2024$1.2BDec 2024$1.2BMar 2025$1.2BJun 2025$1.2BSep 2025$1.2BDec 2025$1.2BMar 2026$1.2BJun 2026
Balance dateTotal debtDue within a yearLong-term debtCash
Jun 2026$1.17B$5M$1.17B$223M
Mar 2026$1.22B$5M$1.22B$245M
Dec 2025$1.22B$305M$920M$363M
Sep 2025$1.22B$304M$920M$296M
Jun 2025$1.22B$304M$921M$293M
Mar 2025$1.22B$304M$921M$307M
Dec 2024$1.22B†$5M$1.22B$321M
Sep 2024$1.22B†$5M$1.22B$299M
Jun 2024$1.22B†$5M$1.22B$344M
Mar 2024$808M†$10M$798M$179M
Dec 2023$871M†$14M$857M$194M
Sep 2023$762M†$14M$749M$351M

† Sum of the debt lines the company reports at that date, not a reported total.

When it comes due

Principal due by year as of June 27, 2026.

Principal due
Within 1 yearWithin 1 year$13MYear 2Year 2$19MYear 3Year 3$1.2BYear 4Year 4$74,000
DuePrincipalShare of total
Within 1 year$13M1.1%
Year 2$19M1.6%
Year 3$1.15B97.3%
Year 4$74,0000.0%
Total$1.18B100%

Interest cost and borrowing

Fiscal yearInterest expenseBorrowedRepaidConvertible notes issuedConvertible notes repaid
FY Mar 2026$19M——$0$300M
FY Mar 2025$36M—$5M$700M$186M
FY Mar 2024$20M—$12M$0$0
FY Apr 2023$13M—$10M$0—
FY Apr 2022$6M—$18M$0—

About these figures

These are the balances Haemonetics reports in its SEC filings as of each balance-sheet date, and the interest, borrowing and repayments it reports for each period. This page does not show market prices or yields of the company's bonds. "Long-term debt" is the line as the company tags it in its filings and may or may not include the portion due within a year.

Financial history →

All figures from company filings with the SEC.

This content is for informational purposes only and is not investment advice. Always do your own research before making financial decisions.